Malignant pleural mesothelioma: a problematic review

Size: px
Start display at page:

Download "Malignant pleural mesothelioma: a problematic review"

Transcription

1 Surgical Oncology 7 (1999) 5}12 Review Malignant pleural mesothelioma: a problematic review Thomas L. Moskal*, John D. Urschel, Timothy M. Anderson, Joseph G. Antkowiak, Hiroshi Takita- Division of Surgical Oncology and Department of Thoracic Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buwalo, New York, USA Abstract Malignant pleural mesothelioma is a rare tumor that has been di$cult to study. Because of disappointing treatment results, malignant pleural mesothelioma has remained an area of active research and development. A clinicopathologic review is performed in light of several problematic issues involving diagnosis, staging, natural history, and treatment. Multimodality treatment with surgery followed by adjuvant local and systemic therapy remains the most optimal therapy. Many controversial issues still exist in the treatment of malignant pleural mesothelioma. In the ensuing years newer staging systems, better preoperative staging, newer experimental therapies, and the localization of patients at expert centers will undoubtedly have an impact on disease management Published by Elsevier Science Ltd. All rights reserved. Keywords: Mesothelioma; Pleural neoplasm; Lung neoplasm 1. Introduction Malignant mesothelioma is a rare tumor a!ecting a variety of mesodermally derived tissues in the body. Pleura is the most commonly a!ected site followed by peritoneum, pericardium, and tunica vaginalis testes. This review will focus on malignant pleural mesothelioma. Etiologic factors, natural history, possible therapeutic options as well as future directions in the management of malignant pleural mesothelioma will be overviewed. Multiple controversial issues exist concerning the diagnosis, staging, and treatment of malignant pleural mesothelioma, and contemporary solutions to these issues will be discussed. Responses to primary therapies are strikingly disappointing making malignant pleural mesothelioma an important disease in the study of innovative oncological therapies. *Corresponding author: North Shore Surgical Oncology Associates. 600 Northern Boulevard, Great Neck, New York 11021, Tel.: # ; fax: # Reprint requests should be addressed to Dr Hiroshi Takita, Department of Thoracic Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Bu!alo, New York, 14263, USA. Tel.: # ; fax: # Epidemiology Malignant pleural mesothelioma (MPM) did not become a clinical entity until "rst reported by Wagner in 1960 when he described 33 cases of malignant pleural mesothelioma [1]. It is a rare disease with 2000 cases occurring annually in the United States [2]. This combination of low incidence in a recently discovered disease has made the study of MPM di$cult. Clinical information stems mostly from single institution case series with small numbers of patients. Signi"cant clinical work has been completed in other rare malignancies, such as sarcoma and Wilm's tumor, utilizing well designed prospective, randomized, multi-institutional trials. Such study design techniques will have to be extrapolated to MPM research. When malignant pleural mesothelioma was described in the 1960s the majority of cases were in asbestos mine workers. Soon after, epidemiologic studies "rmly established asbestos as the primary etiologic factor for malignant pleural mesothelioma [3]. Asbestos is the commercial name for hydrated magnesium silicate "bers. These "bers possess high tensile strength, high stability and high thermal resistant properties. These attractive properties along with its inexpensive price have made asbestos a commonly used manufacturing material. There is a long latent period of 20}50 yr prior to /99/$ - see front matter 1999 Published by Elsevier Science Ltd. All rights reserved. PII: S ( 9 8 ) X

2 6 T.L. Moskal et al. / Surgical Oncology 7 (1999) 5}12 developing MPM after exposure [4]. Sixty to 80% of patients with MPM have a history of exposure to asbestos [4]. Occupations at risk include miners, railroad workers, shipyard workers, construction workers, plumbers, and carpenters. Other possible etiologic factors for MPM include sporadic cases, passive or occult exposure to asbestos, exposure to radiation, exposure to other industrial "bers such as zeolite, exposure to beryllium and tuberculosis [4, 5]. Legislation has been implemented in the United States to minimize occupational and environmental asbestos exposure since the early 1970s. However, worldwide asbestos use has been underregulated and one can only conclude that the incidence of pleural mesothelioma will continue to rise. 3. Patient characteristics A recent review of 40 patients at Roswell Park Cancer Institute (RPCI) revealed the following patient characteristics. Median age was 59 yr; age range was from 21 to 77 yr. Male patients outnumbered female patients in a ratio of 3.4 : 1. Right sided lesions predominated over left sided lesions in a ratio of 2.6 : 1. Seventy-eight percent of patients had a history of exposure to asbestos. In this same series, presenting symptoms included dyspnea in 50%, chest pain in 33%, and cough in 23%; 15% of lesions were asymptomatic. Less frequently seen symptoms were chest wall mass and weight loss, each seen 3% of the time. Fig. 1. Chest X-ray of patient with left sided pleural mesothelioma with moderate pleural e!usion. 4. Diagnosis A typical chest X-ray (Fig. 1) of a patient with MPM demonstrates a moderate pleural e!usion. A typical computed tomographic (CT) scan (Fig. 2) in a patient with MPM demonstrates di!use pleural thickening in the chest. In the RPCI series radiographic "ndings included a pleural e!usion in 77%, a combination of pleural e!usion and pleural-based mass in 8%, and a solitary pleural mass in 15%. During the "rst three decades of MPM research, the histologic diagnosis was very di$cult to make. It was often impossible to di!erentiate malignant pleural mesothelioma from adenocarcinoma. Because of these interpretative di$culties, the early literature must be scrutinized. In the 1980s electron microscopy became the gold standard for histologic diagnosis. In the 1990s immunohistochemical staining has made histologic diagnosis even easier. By way of a body of immunohistochemical stains (see Table 1), the accurate diagnosis of MPM and di!erentiation from adenocarcinoma is now possible [4]. Periodic acid Schi! stain with diastase digestion, mucicarmine, carcino-embryonic antigen and Fig. 2. CT scan of patient with left sided pleural mesothelioma with di!use pleural thickening. leukocyte M1 antibody staining seem to be the most useful. There are three main histologic subtypes for MPM. In the RPCI series the epithelial subtype was the most commonly seen accounting for 62%. The biphasic subtype accounted for 25%, whereas the sarcomatous subtype was least frequently seen accounting for 13%.

3 T.L. Moskal et al. / Surgical Oncology 7 (1999) 5}12 7 Table 1 Immunohistochemical staining Stain Mesothelioma Adenocarcinoma PAS #/! # DPAS! # Hyaluronic acid #/!!/# Mucicarmine! # Keratin # # CEA! # Leu-M1! # Vimentin #/!!/# PAS, periodic acid shi!; DPAS, diastase digested PAS; CEA, carcinoembryonic antigen; Leu-M1, leukocyte M1 antibody. In the RPCI series diagnosis was achieved by thoracentesis in 2%, percutaneous biopsy in 13%, open thoracotomy biopsy in 35%, and video assisted thoracoscopic biopsy in 50%. In 1993, Boutin reviewed 188 consecutive patients comparing thoracentesis, CT guided "ne needle aspiration biopsy and thoracoscopic assisted biopsy as diagnostic tools in MPM [6]. Although thoracentesis was performed in the majority of patients for their pleural e!usions, it was only useful 26% of the time. CT guided "ne needle aspiration biopsy was useful 21% of the time. Finally, thoracoscopic assisted biopsy was most useful in obtaining a diagnosis in 98% of patients. Ultimately, as percutaneous biopsy instrumentation and immunohistochemistry improve, the feasibility of CT scan guided percutaneous biopsy will increase as a diagnostic tool. Scott in 1995 achieved diagnostic accuracy of 93% in 42 patients and Metintas in 1995 achieved diagnostic accuracy of 83% in 30 patients undergoing CT guided percutaneous biopsy for MPM [7, 8]. A problem with invasive histologic sampling in the diagnosis of MPM is the potential for malignant tract seeding which can be seen in 19% of patients [9]. In 1995 Boutin studied the role of radiation therapy to decrease disease seeding from diagnostic procedures in 40 patients undergoing video assisted thoracoscopic biopsy. For the 20 patients without radiation therapy treatment to their biopsy tract, eight of those patients developed tract seeding. For the 20 patients treated with local radiation to their biopsy tract, none of those patients developed tract seeding. Commonly found laboratory abnormalities in pleural mesothelioma include elevations in platelet counts and liver function tests. Consistent elevations are not seen although in some studies elevated platelet counts were signi"cant prognostic factors [10, 11]. In the RPCI series 35% of patients had platelet counts greater than and 23% had nonspeci"c elevations in lactate dehydrogenase and alkaline phosphatase. Preoperative platelet count was a signi"cant prognostic factor only on univariate analysis in this series. 5. Staging Since 1970, there have been "ve staging sytems for MPM, making interpretation and comparison of studies di$cult. As the natural history of MPM is further clari"- ed, the staging systems are evolving to incorporate this newer information. The Butchart system is the initial staging system described in 1970 [12]. This four stage system is still used by some today. In the late 1980s and early 1990s the International Union Against Cancer proposed a tumor, node, and metastasis (TNM) staging system. In the 1998 American Joint Committee on Cancer TNM staging system T stage is de"ned as T1 (pleural), T2 (beyond pleura), T3 (chest wall or mediastinal organ invasion), and T4 (direct extension outside of the chest); while nodal disease is de"ned in a similar manner to lung cancers with N1 (hilar), N2 (mediastinal), and N3 (contralateral or supraclavicular) [13]. These are then grouped into four stages with stage I having no nodal involvement. In 1996, the International Mesothelioma Interest Group introduced a newer TNM Staging system taking into account emerging T and N status prognostic factors [14]. In this system T1a (parietal pleura) and T1b (visceral pleura) further separate stage I into stage IA and IB, and stage II now also has no nodal involvement. Clinical staging has been di$cult in pleural mesothelioma. CT scan radiologic imaging has been the most e$cacious test, yet accuracy rates are low. In the RPCI series preoperative CT scanning determined stage correctly in only 30% of the patients. Magnetic resonance imaging (MRI) and positron emission tomographic (PET) scanning are being studied as alternative imaging techniques with mixed results. The roles of mediastinoscopy and thoracoscopy are also being de"ned. Pathologic staging is di$cult in part because resections are often performed piecemeal. Analysis of specimens requires a dedicated surgical and pathology team for proper stage determination. As the need to select patients for di!erent treatment regimens arises, the development of a de"nitive staging system and better preoperative assessment will become necessary. 6. Natural history The natural history of MPM involves a di!use local process a!ecting the pleural surfaces. Lung, diaphragm, pericardium, and mediastinum are invaded resulting in increasing pleural e!usion and lung parenchymal trapping. Patients develop progressive symptoms of dyspnea, cough and chest wall pain. Death usually occurs from respiratory failure. In 1989 Ru$e clearly described the metastatic potential of malignant pleural mesothelioma [11]. He reviewed 92 autopsies and in 49% of the patients distant

4 8 T.L. Moskal et al. / Surgical Oncology 7 (1999) 5}12 metastases were found in the liver, contralateral lung, adrenal gland, kidney, bone and pancreas. Recent reports reveal that two-thirds of patients recur locally and 50}75% at distant sites after treatment. In 1997 King published an autopsy series in which 10 out of 15 patients (67%) had distant metastasis to omentum, stomach, intestine, mesentery, adrenal gland, ovary, pancreas, kidney, liver, spleen, and vertebrae [15]. Sixty seven percent of patients also had recurrence in the contralateral lung. In 1997 Baldini showed that in 46 patients treated with trimodality therapy local recurrence occurred in 35% and distant recurrence in 51% [16]. Initial treatment of pleural mesothelioma consisted of local therapy only. From the described natural history it is clear that treatment options need to address both local and systemic disease. Treatment options for MPM include supportive care, surgery, chemotherapy, radiation therapy, multimodality therapy, photodynamic therapy, intrapleural therapy, immunotherapy, and experimental therapies. 7. Primary single modality therapy Supportive care in the treatment of MPM involves thoracentesis and pleurodesis to control pleural e!usions and dyspnea. Analgesia is also used to control the severe chest wall pain that is often seen. In 1989 Ru$e reviewed 176 patients treated with supportive care, and his median survival was 6.8 months [11]. A controversial issue in the treatment of MPM with surgery is the exact extent of surgery. There is an ongoing debate comparing pleurectomy with extrapleural pneumonectomy. Pleurectomy is associated with lower morbidity and mortality, and preservation of pulmonary function. Extrapleural pneumonectomy is associated with higher morbidity and mortality, a more complete resection of the tumor, and easier feasibility to deliver postoperative radiation therapy. Table 2 includes several series showing the mortality for pleurectomy ranging from 0 to 3.7% [17}20] and for extrapleural pneumonectomy ranging from 5 to 15% [11, 21}23]. In 1996 Sugarbaker, with the largest series of patients, has decreased the contemporary mortality for extrapleural pneumonectomy to 5%. Radiation therapy, as a single modality therapy for MPM, has disappointing results. In 1973 Eshuege treated 14 patients with doses ranging from 35 to 75 gray and observed a median survival of 15 months [24]. In 1981 Gordon treated 27 patients with doses ranging from 10 to 56 gray and observed a median survival of 11.5 months [25]. In 1988 Alberts treated 13 patients with 40 to 80 gray and observed a median survival of 7.8 months [26]. These survivals are not much better than treatment with supportive care. Table 2 Mortality for pleurectomy and pneumonectomy Study Year n Surgery Mortality (%) Hilaris [17] Pleurectomy 0 Rusch [18] Pleurectomy 3.7 Lee [19] Pleurectomy 0 Colleoni [20] Pleurectomy 0 DaValle [21] Pneumonectomy 9.1 Ru$e [11] Pneumonectomy 13 Rusch [22] Pneumonectomy 15 Sugarbaker [23] Pneumonectomy 5 Single agent chemotherapy as a primary single modality therapy for MPM has disappointing results. The responses are low, ranging from 0 to 37%, and the most e$cacious agents seem to be cisplatin, mitomycin C and doxorubicin [27, 28]. Multiple agent chemotherapy for the treatment of MPM also has disappointing results. Responses are slightly better ranging from 0 to 44% [27, 28]. In 1993, the Cancer and Leukemia Group B published its results comparing two di!erent multiple drug regimens [29]. There were 26% responses for a combination of cisplatin and mitomycin C, and 14% responses for a combination of doxorubicin and cisplatin. In 1996 Huncharek compared the results of the treatments with di!erent single modality therapies [30]. In his supportive care group (n"26), median survival was 4.5 months; for surgery alone (n"17), it was 5.0 months; for radiation alone (n"4) 11.5 months; and for chemotherapy (n"11) it was 6.0 months. Interestingly, 21 patients were also treated with multimodality therapy consisting of surgery followed by adjuvant chemotherapy with a superior survival of 23.9 months. 8. Multimodality therapy Many series have shown the potential bene"t of multimodality therapy increasing survival in MPM (see Table 3). In many of these series the staging is variable and because of these selection biases study comparisons must be done cautiously. The combination of chemotherapy and radiation therapy demonstrates median survivals ranging from 7.9 to 11 months [26, 31, 32]. In 1988 Alberts, utilizing a combination of radiation therapy and doxorubicin in 10 patients, had improved median survival of 22.6 months [26]. The combination of surgery followed by systemic chemotherapy, followed by radiation therapy remains an attractive treatment because of its availability at most medical centers [21, 23, 33]. In 1992 Mattson had an

5 T.L. Moskal et al. / Surgical Oncology 7 (1999) 5}12 9 Table 3 Multimodality therapy Study Treatment Year n Median survival (months) OS (2 yr) (%) Chahinian [31] C, XRT NA Sino! [32] C, XRT NA Alberts [26]* C, XRT NA Alberts [26]* C, XRT NA Alberts [26]* C, XRT NA Alberts [26]* C, XRT NA Mattson [33] S, C, XRT DaValle [34] S, C, XRT Sugarbaker [23] S, C, XRT Hilaris [17] S, B, XRT Lee [19] S, IPC Rusch [18] S, IPC, C Rice [35] S, IPC, C Sauter [36] S, IPC, C Colleoni [20] S, IPC, C OS, overall survival; C, systemic chemotherapy; XRT, external beam radiation therapy; S, surgery; B, brachytherapy; IPC, intrapleural chemotherapy; and NA, not available. *Di!erent chemotherapeutic agents. overall survival at 2 yr of 20 %, but this was an inconsistent study in that the adjuvant chemotherapy was comprised of various combinations of seven di!erent chemotherapeutic agents [33]. In 1994 DaValle had an overall survival of 23%, but this was also an inconsistent study in that only 52% of patients had adjuvant chemotherapy [34]. In 1996 Sugarbaker had an overall survival at 2 yr of 45% utilizing a regimen of cyclophosphamide, doxorubicin and cisplatin [23]. In 1983 Hilaris looked at surgery followed by brachytherapy, followed by radiation therapy in 41 patients, demonstrating a median survival of 21 months and overall survival at 2 yr of 40% [17]. In 1995 Lee looked at surgery followed by intrapleural chemotherapy utilizing cisplatin and cytosine arabinoside in 15 patients, revealing median survival of 11.5 months and overall survival at 2 yr of 16% [19]. Several series have looked at the combination of surgery followed by intrapleural chemotherapy, followed by systemic chemotherapy [18, 20, 35, 36]. In 1994 Rusch had overall survival at 2 yr of 40% utilizing a regimen of intrapleural cisplatin and mitomycin C followed by systemic cisplatin and mitomycin C [18]. In 1994 Rice utilizing a similar regimen demonstrated 2 yr overall survival of 25% [35]. In 1995 Sauter looked at intrapleural cisplatin followed by cytosine arabinoside, followed by intravenous cisplatin and mitomycin C with overall survival at 2 yr of 15% [36]. In 1996 Colleoni utilized intrapleural cisplatin and cytosine arabinoside followed by systemic epirubicin and mitomycin C with overall survival at 2 yr of 34% [20]. 9. Experimental therapy The results of MPM treatment are disappointing with low overall 2-yr survival in most cases and with 5-yr overall survivals approaching 0%. Because of these disappointing treatment results with conventional therapy using combinations of surgery, chemotherapy, and radiation therapy, pleural mesothelioma has become an arena for the implementation of new and emerging therapies such as immunotherapy, gene therapy, and photodynamic therapy [37]. Clinical trials with immunotherapy have centered on cytokine therapy. Vaccine treatments are beginning to enter into human treatment protocols. In 1991 Boutin looked at intrapleural interferon-gamma with low responses of 23% in 22 patients [38]. In 1991 Eggermont looked at interleukin-2 given intrapleurally with responses of 24% in 17 patients [39]. Astoul also looked at interleukin-2 given intrapleurally in 15 patients with response rates of 47% [40]. In 1993 Christmas looked at intravenous interferon-α with responses of 12% in 13 patients [41]. Finally, in 1995 Pass looked at a combination of cisplatin, intravenous interferon-α and tamoxifen in 36 patients with responses of 19% [42]. Gene therapy for the treatment of pleural mesothelioma remains in the early stages of development because of the incomplete understanding of tumor molecular biology and immunology. The main approach has focused on delivery of genes into the tumor cells to generate toxic metabolites. The tumor with the gene is then exposed to the nontoxic substrate to generate the toxic product. The two most common systems are the

6 10 T.L. Moskal et al. / Surgical Oncology 7 (1999) 5}12 bacterial cytosine deaminase gene with the 5-#uorocytosine substrate and the herpes simplex thymidine kinase gene (HSVtk) with the ganciclovir substrate [43, 44]. In 1997 Albeda described a phase I trial with intrapleural gene therapy using the HSVtk gene driven by the Rous sarcoma virus promoter (AdRSVtk) [45]. Photodynamic therapy (PDT) is a surface oriented photochemical induced cytotoxic therapy [46}50]. The technology relies on tumor preferential uptake of agents that when activated by light lead to tumor cytotoxicity. The "rst generation agents have been porphyrin based. In 1990 Feins showed the eradication of mesothelioma tumors implanted in nude mice with PDT therapy [51]. In 1990 Pass showed the clinical feasibility of this trea tment [52]. In 1997, Pass described a phase III trial with surgery and chemo-immunotherapy (cisplatin, interferon-α-2b, and tamoxifen) and PDT in 48 patients demonstrating no bene"t from PDT with both groups having median survivals of 14 months [53]. However, this study accrued only 48 out of the required 88 patients and there were only eight patients with early stage I or II disease. Takita treated 40 patients with a combination of surgery and photodynamic therapy in the RPCI series [54]. For the patients with early stage I and II disease (n"13), median survival of 36 months and overall survival at 2 yr was 61%. However, for patients with stage III and IV disease (n"24), median survival was 10 months and 2 yr overall survival was 0%. For the combined patients (n"37), median survival was 15 months and 2 yr overall survival was 23%. Morbidity was increased for all patients and mortality was increased in patients undergoing pneumonectomy. The addition of systemic therapy to the above regimen is expected to further improve treatment results. E!orts in improving PDT delivery and in developing second generation photosensitizers are actively being pursued [55, 56]. 10. Prognostic indicators Positive prognostic indicators for MPM include epithelial histology [10, 57}62], stage I or II disease [11, 57, 59, 61], negative nodal status [60], and good performance status [57, 62]. Other less frequently described positive prognostic factors in the literature are female gender [10, 57, 62], young age [59], normal platelet count [10, 11], long symptom duration [57], weight loss [61], normal white blood cell count [62], and no history of asbestos exposure [11]. In the RPCI series univariate analysis identi"ed stage, completeness of resection, N stage, T stage, histology, platelet count, chest wall muscle invasion, and length of hospital stay as prognostic factors. On multivariate analysis stage, length of hospital stay, PDT dose, and N stage remained prognostic factors. 11. Conclusions Malignant pleural mesothelioma is a rare disease that has been di$cult to study. No standard therapies exist to date. Treatment results are generally disappointing with very few long term survivors. Multimodality therapy with surgery and adjuvant local and systemic therapy seem to give the most favorable outcomes. Aggressive therapy seems most appropriate for patients with early stage I and II disease. This review has touched upon some of the problematic issues in the treatment of malignant pleural mesotheliomas particularly concerning diagnosis, staging, and di$culty with clinical trials. Future directions to help advance malignant pleural mesothelioma treatment will most likely concentrate e!orts on several key points. A uniform staging system must be widely accepted to allow better treatment planning and comparison of outcomes. Better preoperative staging may come with application of MRI, PET scanning or video assisted thoracoscopic staging. Experimental therapies such as tumor vaccines, monoclonal antibody targeting, biologic modi"ers, immunotherapy, photodynamic therapy, and gene therapy are already entering clinical trials. Maximal bene"ts will most likely be generated by concentrating patients at expert centers and organizing clinical trials. References [1] Wagner, JC, Sleggs, CA, Marchand, P. Di!use pleural mesothelioma and asbestos exposure in Northwestern Cape Province. British Journal of Industrial Medicine 1960;17:260. [2] Price B. Analysis of current trends in the United States mesothelioma incidence. American Journal of Epidemiology, 1997;145(3):211}18. [3] Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993;103(4):373S}6S. [4] Chahinian PA, Rusch VW. Malignant mesothelioma. In: Cancer Medicine, Holland J, Bast R, Morton D, Frei E, Kufe D, Weichselbaum R, editors. William and Wilkins Baltimore, Maryland, 1997:1805}26. [5] Hofmann J, Mintzer D, Warhol M. Malignant mesothelioma following radiation therapy. American Journal of Medicine 1994;97:379}82. [6] Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: diagnosis. Cancer 1993;72:389}93. [7] Scott EM, Marshall TJ, Flower CDR, Stewart S. Di!use pleural thickening: percutaneous CT-guided cutting needle biopsy. Radiology 1995;194:867}70. [8] Metintas M, Ozdemir N, Isiksoy S, Kaya T, Ekici M, Erginel S, Harmanci E, Erdinc P, Ulgey N, Alatas F. CT-guided pleural needle biopsy in the diagnosis of malignant mesothelioma. Journal of Computer Assisted Tomography 1995;19(3):370}4. [9] Boutin C, Rey F, Viallat J. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trail of local radiotherapy. Chest 1995;108:754}8. [10] Pass HI, Kranda K, Temeck BK, Feuerstein I, Steinberg SM. Surgically debulked malignant pleural mesothelioma: results

7 T.L. Moskal et al. / Surgical Oncology 7 (1999) 5}12 11 and prognostic factors. Annals of Surgical Oncology 1997;4(3): 215}22. [11] Ru$e P, Feld R, Minkin S, Cormier Y, Boutan-Laroze A, Ginsberg R, Ayoub J, Shepherd FA, Evans WK, Figueredo A, Pater JL, Pringle JF, Kreisman H. Di!use malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. Journal of Clinical Oncology 1989;7(8):1157}68. [12] Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of di!use malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976;31:15}24. [13] American Joint Committee on Cancer, Pleural mesothelioma. In AJCC Cancer Staging Handbook. Fleming I, Cooper J, Henson D, Hutter R, Kennedy B, Murphy G, O'Sullivan B, Sobin L, Yarbro J, editors. Lippincott-Raven Publishers New York 1998:129}31. [14] Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996;14:1}12. [15] King JAC, Tucker JA, Wong SW. Mesothelioma: a study of 22 cases. Southern Medical Journal 1997;90(2):199}205. [16] Baldini EH, Recht A, Strauss GM, DeCamp MM, Swanson SJ, Liptay MJ, Mentzer SJ, Sugarbaker DJ. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Annals of Thoracic Surgery 1997;63:334}8. [17] Hilaris BS, Nori D, Kwong E, Kutcher GJ, Martini N, Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. International Journal of Radiation Oncology 1984;10:325}31. [18] Rusch V, Saltz L, Venkatraman E, Ginsberg R, McCormack P, Burt M, Markman M, Kelsen D. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. Journal of Clinical Oncology 1994;12(6):1156}63. [19] Lee JD, Perez S, Wang H, Figlin RA, Holmes EC. Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience. Journal of Surgical Oncology 1995;60:262}7. [20] Colleoni M, Sartori F, Calabro F, Nelli P, Vicario G, Sgarbossa G, Gaion F, Bortolotti L, Toniolo L and Manente P. Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. Tumori 1996;82:53}6. [21] DaValle MJ, Faber LP, Kittle CF, Jensik RJ. Extrapleural pneumonectomy for di!use, malignant mesothelioma. Annals of Thoracic Surgery 1986;42:612}18. [22] Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. Journal Thoracic and Cardiovascular Surgery 1991;102:1}9. [23] Sugarbaker DJ, Garcia JP, Richards WG, Harpole DH, Healy- Baldini E, DeCamp MM, Mentzer SJ, Liptay MJ, Strauss GM, Swanson SJ. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Annals of Surgery 1996;224(3):288}96. [24] Eschwege F, Schlienger M. La radiotherapie des mesotheliomes pleurax malins. Journal of Radiology and Electrology 1973;54: 255}9. [25] Gordon W, Antman KH, Greenberger JS, Weichselbaum RR, Cha!ey JT. Radiation therapy in the management of patients with mesothelioma. International Journal of Radiation Oncology 1982;8:19}25. [26] Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van der Merwe CA. Malignant pleural mesothelioma: a disease una!ected by current therapeutic maneuvers. Journal of Clinical Oncology 1988;6(3):527}35. [27] Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. Journal of Clinical Oncology 1996;14(3): 1007}17. [28] Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998;113:66S}73S. [29] Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, Herndon JE, Aisner J, Ellison RR, Leone L. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. Journal of Clinical Oncology 1993;11(8):1559}65. [30] Huncharek M, Kelsey K, Mark EJ, Muscat J, Choi N, Carey R, Christiani D. Treatment and survival in di!use malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital. Anticancer Research 1996;16:1265}8. [31] Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM. Di!use malignant mesothelioma. Prospective evaluation of 69 patients. Annals of Internal Medicine 1982;96:746. [32] Sino! C, Falkson G, Sandison AG, De Muelenaere G. Combined doxorubicin and radiation therapy in malignant pleural mesothelioma. Cancer Treatment Reports 1982;66:1605. [33] Mattson K, Holsti LR, Tammilehto L, Maasilta P, Pyrhonen S, Mantyla M, Kajanti M, Salminen US, Rautonen J, Kivisaari L. Multimodality treatment programs for malignant pleural mesothelioma using high dose hemithorax irradiation. International Journal of Radiation Oncology 1992;24:643}50. [34] Faber LP. Extrapleural pneumonectomy for di!use, malignant mesothelioma: updated in Annals of Thoracic Surgery 1994;58:1782}3. [35] Rice TW, Adelstein DJ, Kirby TJ, Saltarelli MG, Murthy SR, Van Kirk MA, Wiedemann HP, Weick JK. Aggressive multimodality therapy for malignant pleural mesothelioma. Annals of Thoracic Surgery 1994;58:24}9. [36] Sauter ER, Langer C, Coia LR, Goldberg M, Keller SM. Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation. Journal of Surgical Oncology 1995;60:100}5. [37] Upham JW, Garlepp MJ, Musk AW, Robinson BWS. Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches. Thorax 1995;50:887}93. [38] Boutin C, Nussbaum E, Monnet I, Bignon J, Vanderschueren R, Guerin J, Menard O, Mignot P, Dabouis G, Douillard J. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994;74:2460}7. [39] Eggermont AMM, Goey SH, Slingerland R, Jansen RLH, Oosterom R, Bolhuis RLH, Stoter G. Clinical and immunological evaluation of intrapleural interleukin-2 in malignant pleural mesothelioma: a phase II study (Abstr.). Proceedings of the American Association for Cancer Research 1991;32:206. [40] Astoul P, Viallat J, Laurent JC, Brandely M, Boutin C. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural e!usion. Chest 1993;103(1):209}13. [41] Christmas TI, Manning LS, Garlepp MJ, Musk AW, Robinson BW. E!ect of interferon-alpha 2a on malignant mesothelioma. Journal of Interferon Research 1993;13:9}12. [42] Pass HW, Temeck BK, Kranda K, Steinberg SM, Pass HI. A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Annals of Surgical Oncology 1995;2:214}20. [43] Smythe WR, Hwang HC, Elshami AA, Amin KM, Eck SL, Davidson BL, Wilson JM, Kaiser LR, Albelda SM. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Annals of Surgery 1995;222(1):78}86. [44] Smythe WR, Kaiser LR, Hwang HC, Amin KM, Pilewski JM, Eck SJ, Wilson JM, Albelda SM. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Annals of Thoracic Surgery 1994;57:1395}1401.

8 12 T.L. Moskal et al. / Surgical Oncology 7 (1999) 5}12 [45] Albelda SM. Gene therapy for lung cancer and mesothelioma. Chest 1997;111:144S}9S. [46] Dougherty TJ, Marcus SL. Photodynamic therapy. European Journal of Cancer 1992;28A(10):1734}42. [47] Pass HI. Photodynamic therapy in oncology: mechanisms and clinical use. Journal of the National Cancer Institute 1993; 85(6):443}56. [48] Pass HI, Delaney TF. Photodynamic therapy. In Cancer: Principles and Practice of Oncology, DeVita V, Hellman S, Rosenberg S. editors. Philadelphia: J.B. Lippincott Company, 1993:2687}700. [49] Keller SM. Photodynamic therapy: biology and clinical application. Chest Surgery Clinics of North America 1995;5:121}137. [50] Pass HI, Donnington JS. Use of photodynamic therapy for the management of pleural malignancies. Seminars in Surgical Oncology 1995;11:360}7. [51] Feins RH, Hilf R, Ross H, Gibson SL. Photodynamic therapy for human malignant mesothelioma in the nude mouse. Journal of Surgical Research 1990;49:311}14. [52] Pass HI, DeLaney TF, Russo A, Mitchell J, Smith PD, Friauf W, Thomas GF. Feasibility of intrapleural photodynamic therapy: the "rst eight patients. In: Optical Methods Tumor Treatment Detection. Dougherty T, editor. Bellingham, Washington: SPIE Publications, 1992:2}9. [53] Pass HI, Temeck BK, Kranda K, Thomas G, Russo A, Smith P, Friauf W, Steinberg SM. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Annals of Surgical Oncology 1997;4:628}33. [54] Takita H, Dougherty TJ. Intracavitary photodynamic therapy for malignant pleural mesothelioma. Seminars in Surgical Oncology 1995;11:368}71. [55] Baas P, Murrer L, Zoetmulder FAN, Stewart FA, Ris HB, van Zandwijk N, Peterse JL, Rutgers EJT. Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. British Journal of Cancer 1997;76:819}26. [56] Ris H, Altermatt HJ, Nachbur B, Stewart CM, Wang Q, Lim CK, Bonnett R, Althaus U. Intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin for chest malignancies. Lasers in Surgery and Medicine 1996;18:39}45. [57] Tammilheto L. Malignant mesothelioma: prognostic factors in a prospective study of 98 patients. Lung Cancer 1992;8:175}84. [58] Fusco V, Ardizzoni A, Merlo F, Cinquegrana A, Faravelli B, De Palma M, Chessa L, Nicolo G, Serra M, Capaccio A, Rosso R. Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients. Anticancer Research 1993;13:683}90. [59] Manzini VP, Brollo A, Franceschi S, De Matthaeis M, Talamini R, Bianchi C. Prognostic factors of malignant mesothelioma of the pleura. Cancer 1993;72(2):410}7. [60] Sugarbaker DJ, Strauss GM, Lynch TJ, Richards W, Mentzer SJ, Lee TH, Carson JM, Antman KH. Node status has prognostic signi"cance in the multimodality therapy of di!use, malignant mesothelioma. Journal of Clinical Oncology 1993;11(6): 1172}8. [61] Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: prognosis and staging. Cancer 1993;72:394}404. [62] Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European organization for research and treatment of cancer experience. Journal of Clinical Oncology 1998; 16:145}52.

Surgical Management of Malignant Pleural Mesothelioma: A Clinical Practice Guideline

Surgical Management of Malignant Pleural Mesothelioma: A Clinical Practice Guideline Evidence-based Series #7-14-2: Section 1 Surgical Management of Malignant Pleural Mesothelioma: A Clinical Practice Guideline D.E. Maziak, A. Gagliardi, A.E. Haynes, J.A. Mackay, W.K. Evans, and members

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

Malignant pleural mesothelioma: outcome of limited surgical management

Malignant pleural mesothelioma: outcome of limited surgical management Interactive Cardiovascular and Thoracic Surgery 2 (2003) 30 34 Institutional review Thoracic general Malignant pleural mesothelioma: outcome of limited surgical management Peter G. Phillips a, George Asimakopoulos

More information

Malignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center

Malignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Mesothelioma Current Approaches to a Difficult Problem Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Pleural Mesothelioma Clinical Presentation Insidious

More information

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012 Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos

More information

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the

More information

Mesothelioma. Malignant Pleural Mesothelioma

Mesothelioma. Malignant Pleural Mesothelioma Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency

More information

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

More information

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image

More information

Clinical Indications and Results Following Chest Wall Resection

Clinical Indications and Results Following Chest Wall Resection Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division

More information

A Case of Advanced Malignant Pleural Mesothelioma Treatment with Chemotherapy and Photodynamic Therapy

A Case of Advanced Malignant Pleural Mesothelioma Treatment with Chemotherapy and Photodynamic Therapy CASE REPORT http://dx.doi.org/10.4046/trd.2015.78.1.36 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2015;78:36-40 A Case of Advanced Malignant Pleural Mesothelioma Treatment with Chemotherapy

More information

Malignant Pleural Mesothelioma in Singapore

Malignant Pleural Mesothelioma in Singapore RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods and

More information

Malignant Mesothelioma State of the Art

Malignant Mesothelioma State of the Art Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

Treatment of mesothelioma in Bloemfontein, South Africa

Treatment of mesothelioma in Bloemfontein, South Africa European Journal of Cardio-thoracic Surgery 24 (2003) 434 440 www.elsevier.com/locate/ejcts Treatment of mesothelioma in Bloemfontein, South Africa W.J. de Vries*, M.A. Long Cardiothoracic Department,

More information

MESOTHELIOMA. Not Just a Late Night Commercial. Graciela Hoal, RN, MSN, ACNP-BC

MESOTHELIOMA. Not Just a Late Night Commercial. Graciela Hoal, RN, MSN, ACNP-BC MESOTHELIOMA Not Just a Late Night Commercial Graciela Hoal, RN, MSN, ACNP-BC Saturday Session Thoracic Surgery Nurse Practitioner Greater Los Angeles Veteran Affairs Objectives Course Objectives: Discuss

More information

Sternotomy and removal of the tumor

Sternotomy and removal of the tumor Sternotomy and removal of the tumor All thymomas originate from epithelial thymic cells 4% of them consist of a pure population of epithelial cells Most have mixed populations of lymphoid cells to a

More information

Malignant pleural mesothelioma P/D vs. EPP

Malignant pleural mesothelioma P/D vs. EPP 3 rd International Thoracic Oncology Congress Dresden, September 13 15, 2012 Malignant pleural mesothelioma P/D vs. EPP Walter Weder, MD Professor of Surgery Dokumentenname Datum Seite 1 Extrapleural Pneumonectomy

More information

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of

More information

Ahmed Farouk Abd El-Hafez, MD

Ahmed Farouk Abd El-Hafez, MD Presented By Ahmed Farouk Abd El-Hafez, MD Lecturer of Cardiothoracic Surgery Assiut University Asbestos exposure : amphibole fibers especially crocidolite asbestos Nonasbestos Causes : Silicate fibers

More information

The Proposed New International TNM Staging System for Malignant Pleural Mesothelioma: Application to Imaging

The Proposed New International TNM Staging System for Malignant Pleural Mesothelioma: Application to Imaging 323.....:. #{149} :. #{149}..: #{149}. #{149}. :- : Received June 22, 1995; accepted after revision September 12, 1995. 1 Department of Radiology, Duke University Medical Center, Box 3808, Dunham, NC 2771

More information

Mesothelioma: Questions and Answers

Mesothelioma: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Mesothelioma: Questions

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

Recommendations for the Reporting of Pleural Mesothelioma

Recommendations for the Reporting of Pleural Mesothelioma Recommendations for the Reporting of Pleural Mesothelioma Association of Directors of Anatomic and Surgical Pathology * DOI: 10.1309/6A30YQHBMTHEJTEM It has been evident for decades that pathology reports

More information

prognostic scoring systems. We

prognostic scoring systems. We Thorax 2000;55:731 735 731 Original articles Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems J G Edwards, K R Abrams, J N Leverment,

More information

Post-operative intrapleural chemotherapy for mesothelioma

Post-operative intrapleural chemotherapy for mesothelioma Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy

More information

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,

More information

Treatment of Malignant Pleural Mesothelioma: Is There a Benefit to Pleuropneumonectomy?

Treatment of Malignant Pleural Mesothelioma: Is There a Benefit to Pleuropneumonectomy? 55 Treatment of Malignant Pleural Mesothelioma: Is There a Benefit to Pleuropneumonectomy? Stacey Su, Michael T. Jaklitsch, and David J. Sugarbaker Malignant pleural mesothelioma (MPM) is a rare but highly

More information

Malignant Mesothelioma: an Update

Malignant Mesothelioma: an Update Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers

More information

Surgical therapy of. who should be operated

Surgical therapy of. who should be operated SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, 13th and 14th January 2012 Surgical therapy of mesothelioma, who should be operated Walter Weder MD Professor of Surgery University Hospital Zurich

More information

Contemporary Management of Malignant Pleural Mesothelioma

Contemporary Management of Malignant Pleural Mesothelioma Contemporary Management of Malignant Pleural Mesothelioma ERIC G. BUTCHART University Hospital of Wales, Cardiff, United Kingdom Key Words. Mesothelioma Surgery Radiotherapy Chemotherapy Immunology Gene

More information

Lung Cancer Treatment Guidelines

Lung Cancer Treatment Guidelines Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

Neoplasms of the LUNG and PLEURA

Neoplasms of the LUNG and PLEURA Neoplasms of the LUNG and PLEURA 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 Case 1 Case Vignette HISTORY:

More information

treated and 64 untreated patients

treated and 64 untreated patients Thorax 1984;39:255-259 Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients MR LAW, ANNA GREGOR, MARGARET E HODSON, HJG BLOOM, M TURNER-WARWICK From the Cardiothoracic

More information

Update on Mesothelioma

Update on Mesothelioma November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical

More information

Thoracoscopy in Pleural Malignant Mesothelioma

Thoracoscopy in Pleural Malignant Mesothelioma Diagnostic and Therapeutic Endoscopy, 1997, Vol. 3, pp. 147-151 Reprints available directly from the publisher Photocopying permitted by license only (C) 1997 OPA (Overseas Publishers Association) Amsterdam

More information

Characteristics of Malignant Pleural Mesothelioma in Women

Characteristics of Malignant Pleural Mesothelioma in Women Characteristics of Malignant Pleural Mesothelioma in Women Andrea S. Wolf, MD, MPH, William G. Richards, PhD, Tamara R. Tilleman, MD, PhD, Lucian Chirieac, MD, Shelley Hurwitz, PhD, Raphael Bueno, MD,

More information

Multimodality Therapy of Malignant Pleural Mesothelioma Results in 120 Consecutive Patients

Multimodality Therapy of Malignant Pleural Mesothelioma Results in 120 Consecutive Patients ANNALS OF SURGERY Vol. 224, No. 3. 288-296 C 1996 Lippincott-Raven Publishers Extrapleural Pneumonectomy in the Multimodality Therapy of Malignant Pleural Mesothelioma Results in 120 Consecutive Patients

More information

Understanding Pleural Mesothelioma

Understanding Pleural Mesothelioma Understanding Pleural Mesothelioma UHN Information for patients and families Read this booklet to learn about: What is pleural mesothelioma? What causes it? What are the symptoms? What tests are done to

More information

General Information About Non-Small Cell Lung Cancer

General Information About Non-Small Cell Lung Cancer General Information About Non-Small Cell Lung Cancer Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. The lungs are a pair of cone-shaped breathing

More information

A Practical Guide to Advances in Staging and Treatment of NSCLC

A Practical Guide to Advances in Staging and Treatment of NSCLC A Practical Guide to Advances in Staging and Treatment of NSCLC Robert J. Korst, M.D. Director, Thoracic Surgery Medical Director, The Blumenthal Cancer Center The Valley Hospital Objectives Revised staging

More information

Induction of Apoptosis by Intrapleural Perfusion Hyperthermo-Chemotherapy for Malignant Pleural Mesothelioma

Induction of Apoptosis by Intrapleural Perfusion Hyperthermo-Chemotherapy for Malignant Pleural Mesothelioma Original Article Induction of Apoptosis by Intrapleural Perfusion Hyperthermo-Chemotherapy for Malignant Pleural Mesothelioma Yasunori Matsuzaki, MD, Masaki Tomita, MD, Tetsuya Shimizu, MD, Masaki Hara,

More information

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year

More information

Primary -Benign - Malignant Secondary

Primary -Benign - Malignant Secondary TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very low

More information

P L E U R A L M E S O T H E L I O M A

P L E U R A L M E S O T H E L I O M A For media outside the US, UK and Canada only P L E U R A L M E S O T H E L I O M A 1. Overview 2. What is pleural mesothelioma? 3. How common is pleural mesothelioma? 4. What are the risk factors for pleural

More information

Principal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center

Principal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

PET/CT in Lung Cancer

PET/CT in Lung Cancer PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT

More information

Case Report Pleural Mesothelioma Presenting as Periumbilical Metastasis: The First Clinical Documentation

Case Report Pleural Mesothelioma Presenting as Periumbilical Metastasis: The First Clinical Documentation Volume 2013, Article ID 198729, 4 pages http://dx.doi.org/10.1155/2013/198729 Case Report Pleural Mesothelioma Presenting as Periumbilical Metastasis: The First Clinical Documentation R. F. Falkenstern-Ge,

More information

Clinicopathological Study on Malignant Pleural Mesotheliomas

Clinicopathological Study on Malignant Pleural Mesotheliomas Table of Contents Clinicopathological Study on Malignant Pleural Mesotheliomas PL-4-03 Kenzo Hiroshima Kenzo Hiroshima 1, Akira Iyota 1, Kiyoshi Sibuya 1, Toshikazu Yusa 2, Takehiko Fujisawa 1 and Yukio

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3

ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 HOW TO CITE THIS ARTICLE: Gorantla Sambasivarao, Namballa Usharani,

More information

Lung Cancer: Diagnosis, Staging and Treatment

Lung Cancer: Diagnosis, Staging and Treatment PATIENT EDUCATION patienteducation.osumc.edu Lung Cancer: Diagnosis, Staging and Treatment Cancer begins in our cells. Cells are the building blocks of our tissues. Tissues make up the organs of the body.

More information

Screening, early referral and treatment for asbestos related cancer

Screening, early referral and treatment for asbestos related cancer Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung

More information

Lung Cancer: Diagnosis, Staging and Treatment

Lung Cancer: Diagnosis, Staging and Treatment PATIENT EDUCATION patienteducation.osumc.edu Lung Cancer: Diagnosis, Staging and Treatment Cancer starts in our cells. Cells are the building blocks of our tissues. Tissues make up the organs of the body.

More information

Mesothelioma. 1995-2013, The Patient Education Institute, Inc. www.x-plain.com ocft0101 Last reviewed: 03/21/2013 1

Mesothelioma. 1995-2013, The Patient Education Institute, Inc. www.x-plain.com ocft0101 Last reviewed: 03/21/2013 1 Mesothelioma Introduction Mesothelioma is a type of cancer. It starts in the tissue that lines your lungs, stomach, heart, and other organs. This tissue is called mesothelium. Most people who get this

More information

Surgical treatment of malignant pleural mesothelioma. Experience in the interdisciplinary approach in Slovenia

Surgical treatment of malignant pleural mesothelioma. Experience in the interdisciplinary approach in Slovenia Surgical treatment of malignant pleural mesothelioma. Experience in the interdisciplinary approach in Slovenia Janez Eržen 1, Stanko Vidmar 1, Miha Sok 1, Andrej Debeljak 2, Peter Kecelj 2, Viljem Kovač

More information

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project Data Forms and Fields in CRAB Electronic Data Capture System - Reduced Set - Pivotal data elements for developing

More information

Research Article Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy

Research Article Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy Lung Cancer International Volume 2015, Article ID 590148, 7 pages http://dx.doi.org/10.1155/2015/590148 Research Article Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate

More information

Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org

Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental

More information

Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200

Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200 GUIDE TO ASBESTOS LUNG CANCER What Is Asbestos Lung Cancer? Like tobacco smoking, exposure to asbestos can result in the development of lung cancer. Similarly, the risk of developing asbestos induced lung

More information

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Aggressive lymphomas. Michael Crump Princess Margaret Hospital Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:

More information

Surgical Management of Malignant Pleural Mesothelioma: A Clinical Practice Guideline

Surgical Management of Malignant Pleural Mesothelioma: A Clinical Practice Guideline Evidence-based Series #7-14-2: Section 1 Surgical Management of Malignant Pleural Mesothelioma: A Clinical Practice Guideline D.E. Maziak, A. Gagliardi, A.E. Haynes, J.A. Mackay, W.K. Evans, and members

More information

Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma

Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma I d like to welcome everyone, thanks for coming out to our lunch with experts. The faculty today are great people in the thoracic

More information

Materials and Methods. Results

Materials and Methods. Results Anatomic Pathology / Malignant Pleural Mesothelioma Histologic Assessment and Prognostic Factors of Malignant Pleural Mesothelioma Treated With Extrapleural Pneumonectomy Andrea V. Arrossi, MD, 1 E. Lin,

More information

Avastin: Glossary of key terms

Avastin: Glossary of key terms Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.

More information

J of Evidence Based Med & Hlthcare, pissn- 2349-2562, eissn- 2349-2570/ Vol. 2/Issue 33/Aug. 17, 2015 Page 5063

J of Evidence Based Med & Hlthcare, pissn- 2349-2562, eissn- 2349-2570/ Vol. 2/Issue 33/Aug. 17, 2015 Page 5063 PERITONEAL MALIGNANT MESOTHELIOMA: A RARE S. R. Dhamotharan 1, S. Shanthi Nirmala 2, F. Celine Foustina Mary 3, M. Arul Raj Kumar 4, R. Vinothprabhu 5 HOW TO CITE THIS ARTICLE: S. R. Dhamotharan, S. Shanthi

More information

Carcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in

Carcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition, 2001 Vagina Jeffrey L. Stern, MD Carcinoma of the vagina is

More information

Lung Cancer: Practical Application of Imaging In Determining Resectability. Jeremy J. Erasmus, M. D.

Lung Cancer: Practical Application of Imaging In Determining Resectability. Jeremy J. Erasmus, M. D. Lung Cancer: Practical Application of Imaging In Determining Resectability Jeremy J. Erasmus, M. D. 62 year old man with a superior sulcus tumor. Which of the following precludes surgical resection in

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES LUNG SITE MESOTHELIOMA Lung Site Group Mesothelioma Date Guideline Created: April 2013 Authors: Dr. Meredith Giuliani, Dr. Andrea Bezjak 1.

More information

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University

More information

The Need for Accurate Lung Cancer Staging

The Need for Accurate Lung Cancer Staging The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives

More information

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured

More information

Treatment Guide Lung Cancer Management

Treatment Guide Lung Cancer Management Treatment Guide Lung Cancer Management The Chest Cancer Center at Cleveland Clinic, which includes specialists from the Respiratory Institute, Taussig Cancer Institute and Miller Family Heart & Vascular

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually

More information

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.

More information

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI

More information

Survey of Mesothelioma Associated with Asbestos Exposure in Japan

Survey of Mesothelioma Associated with Asbestos Exposure in Japan The research and development and the dissemination projects related to the 13 fields of occupational injuries and illnesses Survey of Mesothelioma Associated with Asbestos Exposure in Japan Clinical characteristics

More information

A succesfull case of HIPEC in a peritoneal mesothelioma patient

A succesfull case of HIPEC in a peritoneal mesothelioma patient A succesfull case of HIPEC in a peritoneal mesothelioma patient Firmino, NLJ¹²; Miranda, E¹³; Oliveira, DA ²; Lima, MBA ¹²; Diniz, AF ¹²; Gomes, GES ¹²; Azevedo, LW ¹²; Soares,MC¹²; Gomes, ASA³. ¹Pernambuco

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant Mesothelioma What is malignant mesothelioma? Malignant mesothelioma is a cancer that starts in cells in the linings of certain parts of the body, especially in the linings of the chest or abdomen.

More information

British Thoracic Society Standards of Care Committee

British Thoracic Society Standards of Care Committee 250 Thorax 2001;56:250 265 BTS statement Statement on malignant mesothelioma in the United Kingdom British Thoracic Society Standards of Care Committee Correspondence to: Dr J Wiggins, Wexham Park Hospital,

More information

Pre-workshop exercise

Pre-workshop exercise Setting research priorities for mesothelioma workshop 10 th November 2014 Pre-workshop exercise Your individual ranking of unanswered questions about the diagnosis, treatment and care of mesothelioma Please

More information

Radical surgery for malignant pleural mesothelioma: results and prognosis

Radical surgery for malignant pleural mesothelioma: results and prognosis doi:10.1510/icvts.2007.166322 Interactive CardioVascular and Thoracic Surgery 7 (2008) 102 106 www.icvts.org Institutional report - Thoracic general Radical surgery for malignant pleural mesothelioma:

More information

Lung Cancer and Mesothelioma

Lung Cancer and Mesothelioma Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant

More information

It was estimated that 2200 to 3000 new cases of mesothelioma

It was estimated that 2200 to 3000 new cases of mesothelioma RESECTION MARGINS, EXTRAPLEURAL NODAL STATUS, AND CELL TYPE DETERMINE POSTOPERATIVE LONG-TERM SURVIVAL IN TRIMODALITY THERAPY OF MALIGNANT PLEURAL MESOTHELIOMA: RESULTS IN 183 PATIENTS David J. Sugarbaker,

More information

Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson

Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant

More information

1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT

1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT 1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT Learning that your pet has a diagnosis of cancer can be overwhelming. We realize that your pet

More information

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1 1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY

More information

Small cell lung cancer

Small cell lung cancer Small cell lung cancer Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. The lungs are a pair of cone-shaped breathing organs that are found within

More information

People Living with Cancer

People Living with Cancer Patient Guide ASCOInformation for People Living with Cancer ADVANCED LUNG CANCER TREATMENT Recommendations of the American Society of Clinical Oncology Welcome The American Society of Clinical Oncology

More information

What is Mesothelioma?

What is Mesothelioma? What is Mesothelioma? Mesothelioma is a rare type of cancer that develops in the mesothelial cells found in one s body. These cells form membranous linings that surround and protect the body s organs and

More information

Proposed Adjustments to Pathologic Staging of Epithelial Malignant Pleural Mesothelioma Based on Analysis of 354 Cases

Proposed Adjustments to Pathologic Staging of Epithelial Malignant Pleural Mesothelioma Based on Analysis of 354 Cases Original Article Proposed Adjustments to Pathologic Staging of Epithelial Malignant Pleural Mesothelioma Based on Analysis of 354 Cases William G. Richards, PhD 1,2 ; John J. Godleski, MD 2,3 ; Beow Y.

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Surgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW

Surgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW The treatment you receive will depend on your lung cancer type, for example, whether you have a non-small cell lung cancer Adenocarcinoma or Squamous cell carcinoma, and if this is a sub-type with a mutation.

More information

Uterine sarcomas are very rare. They are responsible for only 1 to 5 percent of all malignancies

Uterine sarcomas are very rare. They are responsible for only 1 to 5 percent of all malignancies EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition 2001 Uterus: Uterine Sarcomas Jeffrey L. Stern, MD Uterine sarcomas

More information

Surgeons Role in Symptom Management. A/Prof Cliff K. C. Choong Consultant Thoracic Surgeon Latrobe Regional Hospital GIPPSLAND

Surgeons Role in Symptom Management. A/Prof Cliff K. C. Choong Consultant Thoracic Surgeon Latrobe Regional Hospital GIPPSLAND Surgeons Role in Symptom Management A/Prof Cliff K. C. Choong Consultant Thoracic Surgeon Latrobe Regional Hospital GIPPSLAND Conditions PLEURAL Pleural effusion Pneumothorax ENDOBRONCHIAL Haemoptysis

More information

Management of mesothelioma

Management of mesothelioma Management of mesothelioma Jan.vanmeerbeeck@ugent.be Amsterdam, March 6, 2010 1 management Palliation Symptomatic care Pain Breathlessness Radiotherapy Chemotherapy Surgery Radical (intention to cure)

More information